VIENNA — Results from the phase 3 SELECT-GCA study showed that the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) induces significant and sustained remission in people with new-onset or relapsing giant cell arteritis (GCA). The primary endpoint of sustained remission — the absence of GCA signs or symptoms from weeks 12 to 52 together with adherence …
